Acknowledgement
This study was carried out with the support of Forest Bioresources Department, National Institute of Forest Science (project no. FP0800-2020-02-2022).
References
- NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. 2001. Osteoporosis prevention, diagnosis, and therapy. JAMA 285: 785-795. https://doi.org/10.1001/jama.285.6.785
- Karsenty G, Wagner EF. 2002. Reaching a genetic and molecular understanding of skeletal development. Dev. Cell 2: 389-406. https://doi.org/10.1016/S1534-5807(02)00157-0
- Komori T. 2006. Regulation of osteoblast differentiation by transcription factors. J. Cell. Biochem. 99: 1233-1239. https://doi.org/10.1002/jcb.20958
- Ponzetti M, Rucci N. 2021. Osteoblast differentiation and signaling: established concepts and emerging topics. Int. J. Mol. Sci. 22: 6651.
- Almalki SG, Agrawal DK. 2016. Key transcription factors in the differentiation of mesenchymal stem cells. Differentiation 92: 41-51. https://doi.org/10.1016/j.diff.2016.02.005
- Herpin A, Cunningham C. 2007. Cross-talk between the bone morphogenetic protein pathway and other major signaling pathways results in tightly regulated cell-specific outcomes. FEBS J. 274: 2977-2985. https://doi.org/10.1111/j.1742-4658.2007.05840.x
- Samee N, Geoffroy V, Marty C, Schiltz C, Vieux-Rochas M, Levi G, et al. 2008. Dlx5, a positive regulator of osteoblastogenesis, is essential for osteoblast-osteoclast coupling. Am. J. Pathol. 173: 773-780. https://doi.org/10.2353/ajpath.2008.080243
- Capulli M, Paone R, Rucci N. 2014. Osteoblast and osteocyte: games without frontiers. Arch. Biochem. Biophys. 561: 3-12. https://doi.org/10.1016/j.abb.2014.05.003
- Kim WJ, Shin HL, Kim BS, Kim HJ, Ryoo HM. 2020. RUNX2-modifying enzymes: therapeutic targets for bone diseases. Exp. Mol. Med. 52: 1178-1184. https://doi.org/10.1038/s12276-020-0471-4
- Chen X, Wang Z, Duan N, Zhu G, Schwarz EM, Xie C. 2018. Osteoblast-osteoclast interactions. Connect. Tissue Res. 59: 99-107. https://doi.org/10.1080/03008207.2017.1290085
- Udagawa N, Takahashi N, Akatsu T, Tanaka H, Sasaki T, Nishihara T, et al. 1990. Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc. Natl. Acad. Sci. USA 87: 7260-7264. https://doi.org/10.1073/pnas.87.18.7260
- Takahashi N, Akatsu T, Udagawa N, Sasaki T, Yamaguchi A, Moseley JM, et al. 1988. Osteoblastic cells are involved in osteoclast formation. Endocrinology 123: 2600-2602. https://doi.org/10.1210/endo-123-5-2600
- Yoshida H, Hayashi S, Kunisada T, Ogawa M, Nishikawa S, Okamura H, et al. 1990. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 345: 442-444. https://doi.org/10.1038/345442a0
- Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al. 1998. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA95: 3597-3602. https://doi.org/10.1073/pnas.95.7.3597
- Lee ZH, Kim HH. 2003. Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. Biochem. Biophys. Res. Commun. 305: 211-214. https://doi.org/10.1016/S0006-291X(03)00695-8
- Feng X. 2005. RANKing intracellular signaling in osteoclasts. IUBMB Life 57: 389-395. https://doi.org/10.1080/15216540500137669
- Takayanagi H. 2007. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat. Rev. Immunol. 7: 292-304. https://doi.org/10.1038/nri2062
- Takayanagi H. 2005. Inflammatory bone destruction and osteoimmunology. J. Periodont. Res. 40: 287-293. https://doi.org/10.1111/j.1600-0765.2005.00814.x
- Grigoriadis AE, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, Fleisch HA, et al. 1994. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266: 443-448. https://doi.org/10.1126/science.7939685
- Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, et al. 2002. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell 3: 889-901. https://doi.org/10.1016/S1534-5807(02)00369-6
- Rodan GA, Martin TJ. 2000. Therapeutic approaches to bone diseases. Science 289: 1508-1514. https://doi.org/10.1126/science.289.5484.1508
- Teitelbaum SL. 2000. Bone resorption by osteoclasts. Science 289: 1504-1508. https://doi.org/10.1126/science.289.5484.1504
- Skjodt MK, Frost M, Abrahamsen B. 2019. Side effects of drugs for osteoporosis and metastatic bone disease. Br. J. Clin. Pharmacol. 85: 1063-1071. https://doi.org/10.1111/bcp.13759
- Stafford RS, Drieling RL, Hersh AL. 2004. National trends in osteoporosis visits and osteoporosis treatment, 1988-2003. Arch. Intern. Med. 164: 1525-1530. https://doi.org/10.1001/archinte.164.14.1525
- Watson J, Wise L, Green J. 2007. Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005. Eur. J. Clin. Pharmacol. 63: 843-849. https://doi.org/10.1007/s00228-007-0320-6
- Filleul O, Crompot E, Saussez S. 2010. Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases. J. Cancer Res. Clin. Oncol. 136: 1117-1124. https://doi.org/10.1007/s00432-010-0907-7
- Yuan H, Ma Q, Ye L, Piao G. 2016. The traditional medicine and modern medicine from natural products. Molecules 21: 559.
- Posadzki P, Watson LK, Ernst E. 2013. Adverse effects of herbal medicines: an overview of systematic reviews. Clin. Med. (Lond.) 13: 7-12. https://doi.org/10.7861/clinmedicine.13-1-7
- Fijalkowska A, Muszynska B, Sulkowska-Ziaja K, Kala K, Pawlik A, Stefaniuk D, et al. 2020. Medicinal potential of mycelium and fruiting bodies of an arboreal mushroom Fomitopsis officinalis in therapy of lifestyle diseases. Sci. Rep. 10: 20081.
- Berger RG, Bordewick S, Krahe NK, Ersoy F. 2022. Mycelium vs. fruiting bodies of edible fungi-a comparison of metabolites. Microorganisms 10: 1379.
- Wasser SP. 2014. Medicinal mushroom science: current perspectives, advances, evidences, and challenges. Biomed J. 37: 345-356. https://doi.org/10.4103/2319-4170.138318
- Choi S-H, Lee S-J, Jo W-S, Choi J-W, Park S-C. 2016. Comparison of ingredients and antioxidant activity of the domestic regional Wolfiporia extensa. Korean J. Mycol. 44: 23-30. https://doi.org/10.4489/KJM.2016.44.1.23
- Cuella MJ, Giner RM, Recio MC, Just MJ, Manez S, Rios JL. 1996. Two fungal lanostane derivatives as phospholipase A2 inhibitors. J. Nat. Prod. 59: 977-979. https://doi.org/10.1021/np9604339
- Wu Y, Zhu W, Wei W, Zhao X, Wang Q, Zeng W, et al. 2016. De novo assembly and transcriptome analysis of sclerotial development in Wolfiporia cocos. Gene 588: 149-155. https://doi.org/10.1016/j.gene.2016.05.020
- Esteban CI. 2009. [Medicinal interest of Poria cocos (= Wolfiporia extensa)]. Rev. Iberoam. Micol. 26: 103-107. https://doi.org/10.1016/S1130-1406(09)70019-1
- Cheng S, Eliaz I, Lin J, Thyagarajan-Sahu A, Sliva D. 2013. Triterpenes from Poria cocos suppress growth and invasiveness of pancreatic cancer cells through the downregulation of MMP-7. Int. J. Oncol. 42: 1869-1874. https://doi.org/10.3892/ijo.2013.1902
- Jiang Y, Fan L. 2020. Evaluation of anticancer activities of Poria cocos ethanol extract in breast cancer: in vivo and in vitro, identification and mechanism. J. Ethnopharmacol. 257: 112851.
- Hamuro J, Yamashita Y, Ohsaka Y, Maeda YY, Chihara G. 1971. Carboxymethylpachymaran, a new water soluble polysaccharide with marked antitumour activity. Nature 233: 486-488. https://doi.org/10.1038/233486a0
- Nukaya H, Yamashiro H, Fukazawa H, Ishida H, Tsuji K. 1996. Isolation of inhibitors of TPA-induced mouse ear edema from Hoelen, Poria cocos. Chem. Pharm. Bull. (Tokyo) 44: 847-849. https://doi.org/10.1248/cpb.44.847
- Hwang YH, Jang SA, Lee A, Kim T, Ha H. 2020. Poria cocos ameliorates bone loss in ovariectomized mice and inhibits osteoclastogenesis in vitro. Nutrients 12: 1383.
- Kim SH, Kim KJ, Kang HJ, Son YJ, Choi SW, Lee MJ. 2018. The dual role of oat bran water extract in bone homeostasis through the regulation of osteoclastogenesis and osteoblast differentiation. Molecules 23: 3119.
- Rozen S, Skaletsky H. 2000. Primer3 on the WWW for general users and for biologist programmers. Methods Mol. Biol. 132: 365-386. https://doi.org/10.1385/1-59259-192-2:365
- Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta C(T)) method. Methods 25: 402-408. https://doi.org/10.1006/meth.2001.1262
- Caetano-Lopes J, Canhao H, Fonseca JE. 2007. Osteoblasts and bone formation. Acta Reumatol. Port. 32: 103-110.
- Katagiri T, Yamaguchi A, Komaki M, Abe E, Takahashi N, Ikeda T, et al. 1994. Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J. Cell Biol. 127: 1755-1766. https://doi.org/10.1083/jcb.127.6.1755
- Javed A, Bae JS, Afzal F, Gutierrez S, Pratap J, Zaidi SK, et al. 2008. Structural coupling of Smad and Runx2 for execution of the BMP2 osteogenic signal. J. Biol. Chem. 283: 8412-8422. https://doi.org/10.1074/jbc.M705578200
- Zainal Ariffin SH, Lim KW, Megat Abdul Wahab R, Zainal Ariffin Z, Rus Din RD, Shahidan MA. 2022. Gene expression profiles for in vitro human stem cell differentiation into osteoblasts and osteoclasts: a systematic review. PeerJ. 10: e14174.
- Asagiri M, Takayanagi H. 2007. The molecular understanding of osteoclast differentiation. Bone 40: 251-264. https://doi.org/10.1016/j.bone.2006.09.023
- Ishida N, Hayashi K, Hoshijima M, Ogawa T, Koga S, Miyatake Y, et al. 2002. Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. J. Biol. Chem. 277: 41147-41156. https://doi.org/10.1074/jbc.M205063200
- Boyle WJ, Simonet WS, Lacey DL. 2003. Osteoclast differentiation and activation. Nature 423: 337-342. https://doi.org/10.1038/nature01658
- Kim SH, Yuk HJ, Ryu HW, Oh SR, Song DY, Lee KS, et al. 2019. Biofunctional soyasaponin Bb in peanut (Arachis hypogaea L.) sprouts enhances bone morphogenetic protein-2-dependent osteogenic differentiation via activation of runt-related transcription factor 2 in C2C12 cells. Phytother. Res. 33: 1490-1500. https://doi.org/10.1002/ptr.6341
- Gersbach CA, Byers BA, Pavlath GK, Garcia AJ. 2004. Runx2/Cbfa1 stimulates transdifferentiation of primary skeletal myoblasts into a mineralizing osteoblastic phenotype. Exp. Cell Res. 300: 406-417. https://doi.org/10.1016/j.yexcr.2004.07.031
- Chen D, Zhao M, Mundy GR. 2004. Bone morphogenetic proteins. Growth Fact. 22: 233-241. https://doi.org/10.1080/08977190412331279890
- Feng XH, Derynck R. 2005. Specificity and versatility in TGF-beta signaling through Smads. Annu. Rev. Cell Dev. Biol. 21: 659-693. https://doi.org/10.1146/annurev.cellbio.21.022404.142018